Invention Grant
US07718776B2 Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
有权
人抗OPGL中和抗体作为选择性OPGL途径抑制剂
- Patent Title: Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
- Patent Title (中): 人抗OPGL中和抗体作为选择性OPGL途径抑制剂
-
Application No.: US10408901Application Date: 2003-04-07
-
Publication No.: US07718776B2Publication Date: 2010-05-18
- Inventor: William J. Boyle , Eugene Medlock , John J. Sullivan , Robin L. Elliott , Frank Martin , Haichun Huang
- Applicant: William J. Boyle , Eugene Medlock , John J. Sullivan , Robin L. Elliott , Frank Martin , Haichun Huang
- Applicant Address: US CA Thousand Oaks US NJ Princeton
- Assignee: Amgen Inc.,Medarex, Inc.
- Current Assignee: Amgen Inc.,Medarex, Inc.
- Current Assignee Address: US CA Thousand Oaks US NJ Princeton
- Agency: McDonnell Boehnen Hulbert & Berghoff LLP
- Main IPC: C12P21/08
- IPC: C12P21/08 ; C07K16/00 ; C12P21/04 ; A61K39/395
Abstract:
Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
Public/Granted literature
- US20040023313A1 Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors Public/Granted day:2004-02-05
Information query
